Mylan Announces Appointment of John Montgomery as President, Asia Pacific
PITTSBURGH, October 02, 2007 /PRNewswire-FirstCall/ -- Mylan Inc. today announced the appointment of John Montgomery to the position of President, Asia Pacific following the completion of Mylan's acquisition of Merck's Generics Group today.
Mr. Montgomery has worked for over 30 years in the pharmaceuticals industry and has extensive experience in both patented and generics pharmaceutical products in the UK, U.S. and Asia Pacific regions. At Merck Generics, he served as Regional Director, Asia Pacific, and CEO of Alphapharm, Merck Generic's business in Australia and the country's leading pharmaceutical company as measured by prescriptions. Prior to joining Merck, he spent 18 years with Warner Lambert in the UK, U.S. and Australia in roles including Business Director, Europe; Vice President, Cardiovascular; Vice President of Portfolio Management for North America; and Regional President Australia/New Zealand. He served five years as Chairman of the Generic Medicines Industry Association (GMiA) in Australia.
Mylan Vice Chairman and CEO Robert J. Coury commented: "I have seen first hand that John is a truly skilled leader with the vision that makes him a perfect fit for Mylan. He brings an impressive track record and true depth of experience to our senior team. Asia Pacific is an important region with an attractive growth profile, particularly in Japan. Under John's leadership, his business ranks number one in both Australia and New Zealand, and also ranks as the leading multinational generics company in Japan. I am confident that we are extremely well-placed to leverage the many opportunities we see in the region from our position as a new global leader in the generics and specialty pharmaceutical industry."
Mr. Montgomery said: "I am very pleased to be joining the management team at Mylan and excited to be part of a company that is firmly focused on growing its generics and specialty pharmaceuticals businesses. There are great similarities between the culture and history of Mylan and Alphapharm, as well as the other Asia Pacific companies. This common culture, values and focus, combined with true global scale, will drive growth and reinforce our leading positions in the region, as well as create additional opportunities for our future success."
Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.
Alphapharm is the largest pharmaceutical company in Australia as measured in prescriptions. The company develops, manufactures, markets and distributes generic and specialty prescription medicines. Merck Seiyaku Ltd. (Japan) was formed through the acquisitions of Hoei and Mohan, and is the fourth largest company in Japan's emerging generics market. The company is focused on specific therapeutic categories including antibiotics, oncology, skin and allergy, and metabolic diseases. Pacific Pharmaceuticals is the market leader in generics in New Zealand.
For more information about Mylan, please visit www.mylan.com.
CONTACT: Kris King, Mylan Inc., +1-724-514-1800
Web site: http://www.mylan.com/
Ticker Symbol: (NYSE:MYL)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: October 2007
Recommended for you